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Therapeutic Hypothermia and
Stent Thrombosis
A Nationwide Analysis
Neeraj Shah, MD, MPH,a Rahul Chaudhary, MD,b Kathan Mehta, MD, MPH,c Vratika Agarwal, MD,d Jalaj Garg, MD,a
Ronald Freudenberger, MD,a Larry Jacobs, MD,a David Cox, MD,a Karl B. Kern, MD,e Nainesh Patel, MDa

ABSTRACT
OBJECTIVES This study sought to determine whether “real-world” data supported the hypothesis that therapeutic
hypothermia (TH) led to increased rates of stent thrombosis.
BACKGROUND TH, which is often instituted after cardiac arrest (CA) to improve neurologic outcomes, alters
pharmacokinetics of antiplatelet medications, leading to a theoretical risk of stent thrombosis after percutaneous
coronary intervention (PCI).
METHODS CA patients with acute myocardial infarction undergoing PCI were identiﬁed from the Nationwide Inpatient
Sample from 2006 to 2011, with a deﬁned primary outcome of stent thrombosis. The incidence of stent thrombosis in
patients undergoing TH versus those not undergoing TH was compared using both logistic regression and propensity
score matching.
RESULTS In this dataset, 49,109 CA patients underwent PCI for acute myocardial infarction from 2006 to 2011, of
whom 1,193 (2.4%) underwent TH. The incidence of stent thrombosis in the TH group was 3.9% (43 of 1,193), compared
to 4.7% (2,271 of 47,916) in the no TH group (p ¼ 0.61). Logistic regression showed that TH was not a signiﬁcant
predictor of stent thrombosis with an adjusted odds ratio of 0.71 (95% conﬁdence interval: 0.28 to 1.76; p ¼ 0.46).
Propensity matching was performed to adjust for baseline differences between the TH and no TH groups, matching 1,155
patients in the TH group with 3,399 patients in the no TH group. No difference was observed in the incidence of stent
thrombosis in the TH and the no TH groups after propensity matching (3.5% vs. 6.1%; p ¼ 0.17).
CONCLUSIONS TH does not increase the incidence of stent thrombosis after primary PCI in patients with acute
myocardial infarction presenting as CA. (J Am Coll Cardiol Intv 2016;9:1801–11) © 2016 by the American College of
Cardiology Foundation.
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was ﬁtted with the following covariates with TH as the

(Online Table 1).

outcome: year, age, sex, hypertension, non–insulindependent DM, insulin-dependent DM, coronary

STATISTICAL ANALYSIS. Stata SE 13.1 (StataCorp,

artery disease, CHF, pre-existing renal dysfunction,

College Station, Texas) was used for all analyses,

type of stent implanted, number of stents, use of

accounting for the complex survey design and

hemodynamic support during PCI, bleeding compli-

clustering. For all variables, weighted values of

cations, vascular complications, need for blood trans-

patient-level observations were generated, using pre-

fusions, cardiogenic shock, noncardiogenic shock,

speciﬁed weights in the NIS dataset to produce a na-

acute renal failure not requiring dialysis, acute renal

tionally representative estimate of the U.S. population

failure requiring dialysis or hemoﬁltration, acute liver

of hospitalized patients. Differences between the

failure, acute respiratory failure, hospital teaching

characteristics of patients undergoing TH versus those

status, hospital size, and hospital region. A 1:3 match

not undergoing TH were evaluated using corrected

was then performed based on the propensity score,

weighted Pearson chi-square test for categorical vari-

using a caliper of 0.01 of the logit of the propensity

ables and weighted linear regression or Student t test

score. For each matched cohort of patients in the

for continuous variables. Stent thrombosis incidence

hypothermia and the no hypothermia group, differ-

was computed as the total number of stent thrombosis

ences in categorical outcomes were assessed by per-

events divided by the total number of observations.

forming Cochran Mantel-Haenszel chi-square test

The incidence of stent thrombosis in the TH and

with match-ID as a stratiﬁcation variable along with

the control (i.e., no TH) groups was compared using

survey weights and clusters. For continuous out-

the corrected weighted Pearson chi-square test.

comes, linear regression was used with match-ID as a

A p value of <0.05 was considered signiﬁcant.

stratiﬁcation variable along with survey weights and

Multivariable logistic regression models incorpo-

clusters. The incidence of stent thrombosis between

rating covariates such as TH, patient demographics,

the 2 groups after propensity matching was compared

comorbidities, stent type, number of stents, bleeding

using the Cochran Mantel-Haenszel test.

complications, vascular complications, need for blood
transfusions, shock or end-organ failure, use of

RESULTS

hemodynamic support, and hospital characteristics
were created to determine independent predictors of

From 2006 to 2011, there were 49,109 CA patients

stent thrombosis. The following variables were

with AMI undergoing PCI. Of these, 1,193 (2.4%)

included in the model to identify predictors of

underwent TH. Table 1 shows the baseline character-

stent thrombosis: TH, age, sex, hypertension, DM,

istics of the study population in the TH and the no

coronary artery disease, CHF, pre-existing renal

TH groups.
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T A B L E 1 Baseline Characteristics of CA AMI Patients Undergoing

T A B L E 1 Continued

PCI in the Therapeutic Hypothermia and the No Therapeutic
Patients With Patients Without
Hypothermia
Hypothermia
(n ¼ 1,193)
(n ¼ 47,916) p Value

Hypothermia Subgroups
Patients With Patients Without
Hypothermia
Hypothermia
(n ¼ 1,193)
(n ¼ 47,916) p Value

Demographics
<0.001

Year of admission

Hospital characteristics
Teaching hospital

50.5

52.1

Large hospital bed size

72.5

73.2

Hospital region

6.7

13.9

Northeast

13.1

14.9

2007

3.7

13.3

Midwest

22.7

28.6

2008

10.6

17.8

South

25.0

36.5

2009

9.7

17.8

West

39.2

20.0

2010

24.0

17.8

2011

45.3

19.4
<0.001

18-40

2.9

3.4

41-50

18.2

13.8

51-60

35.8

26.9

61-70

26.3

24.4

71-80

11.0

19.2

>80

5.8

Age (yrs)
Female

59.6  11.7

12.3
63.4  13.3 <0.001

20.9

31.8

<0.001
0.09

0.93
0.007

2006

Age category (yrs)

0.81

Values are % or mean  SD. *Coronary artery disease includes subacute ischemic
heart disease, history of old MI, angina pectoris, other forms of coronary artery
disease, status post percutaneous coronary transluminal angioplasty, and/or history of coronary artery bypass grafting. †Includes chronic kidney disease stages 3
to 5, history of renal transplant, unspeciﬁed renal failure and end-stage renal
disease on hemodialysis or peritoneal dialysis. ‡Includes all patients receiving
blood transfusions during the hospitalization, regardless of whether they received
it for bleeding or for anemia not secondary to bleeding. §Includes septic shock,
unspeciﬁed shock, or “other” (e.g., hypovolemic) shock. ¶Hemodynamic support
includes percutaneous and nonpercutaneous short-term mechanical circulatory
support, intra-aortic balloon counterpulsation, percutaneous cardiopulmonary
bypass and extracorporeal membrane oxygenation.
AMI ¼ acute myocardial infarction; CA ¼ cardiac arrest; DM ¼ diabetes mellitus;
PCI ¼ percutaneous coronary intervention.

Comorbidities
Coronary artery disease*

86.4

82.3

Hypertension

57.6

54.5

0.33

DM

22.0

24.1

0.49

STENT THROMBOSIS INCIDENCE. There were 2,317

1.7

2.5

0.46

stent thrombosis events (4.7%), of which 46 (3.9%)

Non–insulin-dependent
DM

20.3

21.5

0.65

Congestive heart failure

Insulin dependent DM

occurred in the TH group (n ¼ 1,193) and 2,271 (4.7%)
occurred in the no TH group (n ¼ 47,916). There was

33.3

31.1

0.48

Pre-existing renal
dysfunction†

7.0

11.3

0.02

Not on dialysis

6.1

7.5

0.37

p ¼ 0.61). There was a nonsigniﬁcant trend toward an

On dialysis

0.9

3.8

0.03

increase in stent thrombosis incidence with age, with

PCI-related variables

no difference in the stent thrombosis incidence between the TH and the no TH groups (3.9% vs. 4.7%;

stent thrombosis incidence in age groups of 18 to

Type of stent

0.14

40 years, 41 to 50 years, 51 to 60 years, 61 to 70 years,

Bare-metal stent

53.6

47.7

Drug-eluting stent

46.4

52.3

1

62.1

65.2

stent thrombosis incidence in those who received

2

23.9

22.8

drug-eluting stent was not different from those who

3

11.4

8.0

received a bare-metal stent (4.8% vs. 4.6%; p ¼ 0.70).

$4

2.6

4.0

2.7

3.1

0.82

Any bleeding
complications

15.1

14.0

0.64

Need for blood
transfusion‡

12.8

8.0

Number of stents placed

Vascular complications

71 to 80 years and >80 years being 2.4%, 4.1%, 4.5%,
0.17

The incidence of stent thrombosis in those who

0.006

received hemodynamic support was signiﬁcantly
higher than those who did not (6.3% vs. 4.1%;
p < 0.001). The incidence of stent thrombosis
increased with increase in the number of stents

Shock/end-organ failure
Cardiogenic shock

4.8%, 5.4%, and 5.4%, respectively (p ¼ 0.13). The

<0.001

48.8

33.3

Noncardiogenic shock§

1.9

1.7

0.81

Hemodynamic support
use¶

32.9

29.8

0.29

Acute renal failure

implanted, with the stent thrombosis incidence for
1, 2, 3, and $4 stent implantations being 4.1%, 5.3%,
6.2%, and 7.9%, respectively (p < 0.001). The incidence of stent thrombosis was greater in those who

29.1

21.7

0.009

had CHF (5.8%) compared with those who did

Not requiring dialysis

27.1

19.8

0.008

not have CHF (4.2%; p ¼ 0.001). Similarly, stent

Requiring dialysis or
hemoﬁltration

2.1

1.9

0.84

thrombosis incidence was higher in the presence of

Acute liver failure

16.1

5.8

<0.001

cardiogenic shock (6.2% vs. 4.0%; p < 0.001). The

Acute respiratory failure

72.0

43.8

<0.001

incidence of stent thrombosis was higher in those who

Continued in the next column

had a bleeding complication (5.9% vs. 4.5%; p ¼ 0.03)
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or a vascular complication (8.8% vs. 4.6%; p ¼ 0.002);
and

in

those

who

needed

blood

transfusions

(6.3% vs. 4.6%; p ¼ 0.02).
PREDICTORS

OF

STENT

T A B L E 2 Multivariable Logistic Regression Model Showing

Predictors of Stent Thrombosis in the Study Population
(Full Model)

THROMBOSIS. Logistic

regression analysis showed that TH was not a significant predictor of stent thrombosis. The adjusted
odds ratio (OR) of TH in predicting stent thrombosis

Adjusted OR

95% CI

0.71

0.28–1.76

Therapeutic hypothermia

p Value

0.46

Age (18-40 yrs as referent)
41-50

1.72

0.82–3.61

0.15

51-60

1.79

0.88–3.65

0.11

was 0.7 (95% conﬁdence interval [CI]: 0.3 to 1.8;

61-70

1.82

0.89–3.75

0.10

p ¼ 0.46). Age >80 years (OR: 2.1; 95% CI: 1.0 to 4.4;

71-80

2.03

0.97–4.26

0.06

p ¼ 0.05), CHF (OR: 1.2; 95% CI: 1.0 to 1.5; p ¼ 0.05),

>80

2.09

1.00–4.37

0.05

use of hemodynamic support (OR: 1.3; 95% CI: 1.0 to

Female

0.92

0.76–1.13

0.44

1.6; p ¼ 0.04), occurrence of vascular complications

Coronary artery disease*

1.08

0.83–1.40

0.57

(OR: 1.7; 95% CI: 1.1 to 2.6; p ¼ 0.02), and presence

Hypertension

1.01

0.84–1.22

0.92

DM

0.89

0.71–1.12

0.33

Congestive heart failure

1.23

1.00–1.51

0.05

Pre-existing renal dysfunction†

1.00

0.72–1.38

1.00

thrombosis (Table 2). Additionally, there was a pro-

Drug-eluting stent

1.09

0.90–1.32

0.39

gressive increase in the risk of stent thrombosis with

Number of stents (1 as referent)

of cardiogenic shock (OR: 1.3; 95% CI: 1.0 to 1.6;
p ¼ 0.04) were independent predictors of stent

increasing number of stents implanted: 2 stents

2

1.27

1.03–1.58

0.03

(OR: 1.3; p ¼ 0.03), 3 stents (OR: 1.4; p ¼ 0.07), and $4

3

1.35

0.97–1.87

0.07

$4

1.75

1.17–2.63

0.007

Hemodynamic support use‡

1.27

1.02–1.59

0.04

Vascular complications

1.69

1.09–2.64

0.02

Any bleeding

1.15

0.89–1.49

0.28

wise regression, forward selection, and backward

Need for blood transfusion§

1.15

0.84–1.58

0.37

elimination methods are shown in Online Tables 2

Cardiogenic shock

1.26

1.01–1.57

0.04

1.18

0.61–2.27

0.62

stents (OR: 1.8; p ¼ 0.01) (Table 2).
Reduced models generated using the least absolute
shrinkage and selection operator method and step-

and 3, respectively. Notably, stepwise, forward and

Noncardiogenic shock¶

backward regression methods yielded the exact same

Acute renal failure

1.12

0.89–1.40

0.34

variables; therefore, the same reduced model was

Acute liver failure

0.95

0.64–1.40

0.80

generated with these 3 methods (Online Table 3). The

Acute respiratory failure

1.01

0.83–1.23

0.94

Teaching hospital

1.16

0.95–1.42

0.14

Large hospital bed size

1.18

0.94–1.48

0.15
0.36

Akaike information criterion and Bayesian information criterion values of the full model were not

Hospital region (West as referent)

different from those of the reduced models, and were

Northeast

1.16

0.84–1.61

in fact slightly lower with the full model. Moreover,

Midwest

0.88

0.66–1.17

0.38

the odds ratios and p values of important predictors

South

1.07

0.81–1.42

0.63

such as TH, number of stents, hemodynamic support
use, vascular complications, CHF, and cardiogenic
shock were similar in the full and reduced models
(Table 2, Online Tables 2 and 3). Therefore, only the
results of the full model are presented.
PROPENSITY-MATCHED ANALYSIS. Using

propen-

sity score analysis, we were able to match 1,155
patients in the TH group with 3,399 patients in the no
TH group. Table 3 shows that the baseline character-

For the model, AIC ¼ 18522.471 and BIC ¼ 18529.672. *Coronary artery disease
includes subacute ischemic heart disease, history of old MI, angina pectoris, other
forms of coronary artery disease, status post percutaneous coronary transluminal
angioplasty, and/or history of coronary artery bypass grafting. †Includes chronic
kidney disease stages 3 to 5, history of renal transplant, unspeciﬁed renal failure
and end-stage renal disease on hemodialysis or peritoneal dialysis. ‡Hemodynamic
support includes percutaneous and nonpercutaneous short-term mechanical circulatory support, intra-aortic balloon counterpulsation, percutaneous cardiopulmonary bypass and extracorporeal membrane oxygenation. §Includes all patients
receiving blood transfusions during the hospitalization, regardless of whether they
received it for bleeding or for anemia not secondary to bleeding. ¶Includes septic
shock, unspeciﬁed shock, or “other” (e.g., hypovolemic) shock.
AIC ¼ Akaike information criterion; BIC ¼ Bayesian information criterion;
CI ¼ conﬁdence interval; OR ¼ odds ratio; other abbreviations as in Table 1.

istics in the TH and no TH groups were well-balanced
after propensity matching. There was no difference
in the incidence of stent thrombosis in the TH

those who did not experience stent thrombosis

group (3.6%) compared with the no TH group (6.1%;

(26.4%; p ¼ 0.42).

p ¼ 0.17) after propensity matching.

LENGTH OF STAY. Overall, the average mortality-free

IN-HOSPITAL MORTALITY. Overall, the in-hospital

LOS was 8.8 days. In the overall population, the

mortality rate was 26.3%. The in-hospital mortality

average mortality-free LOS was higher in the TH

rates did not differ signiﬁcantly in those who expe-

group compared with the no TH group (13.0 

rienced stent thrombosis (24.8%) compared with

10.2 days vs. 8.7  8.9 days; p < 0.001), whereas the
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T A B L E 3 Baseline Characteristics in the Therapeutic

T A B L E 3 Continued

Hypothermia and the No Therapeutic Hypothermia Subgroups
Patients With
Hypothermia
(n ¼ 1,155)

After Propensity Score Matching
Patients With
Hypothermia
(n ¼ 1,155)

Patients Without
Hypothermia
(n ¼ 3,399) p Value

Demographics
Year of admission

0.98

Patients Without
Hypothermia
(n ¼ 3,399) p Value

Hospital characteristics
Teaching hospital

50.9

50.7

Large hospital bed size

72.5

72.0

Hospital region

6.9

7.5

Northeast

13.5

11.2

2007

3.8

4.5

Midwest

21.9

22.1

2008

10.9

9.8

South

25.8

30.8

2009

10.1

10.4

West

38.8

35.9

2010

24.8

26.2

2011

43.5

41.5
0.92

18-40

3.0

3.0

41-50

18.4

19.5

51-60

35.7

34.1

61-70

25.6

23.4

71-80

11.3

12.2

>80

6.0

7.8
60.3  12.2 0.39

0.89
0.47

2006

Age category, yrs

0.97

Values are % or mean  SD. *Coronary artery disease includes subacute ischemic
heart disease, history of old MI, angina pectoris, other forms of coronary artery
disease, status post percutaneous coronary transluminal angioplasty, and/or history of coronary artery bypass grafting. †Includes chronic kidney disease stages 3
to 5, history of renal transplant, unspeciﬁed renal failure and end-stage renal
disease on hemodialysis or peritoneal dialysis. ‡Includes all patients receiving
blood transfusions during the hospitalization, regardless of whether they received
it for bleeding or for anemia not secondary to bleeding. §Includes septic shock,
unspeciﬁed shock, or “other” (e.g., hypovolemic) shock. ¶Hemodynamic support
includes percutaneous and nonpercutaneous short-term mechanical circulatory
support, intra-aortic balloon counterpulsation, percutaneous cardiopulmonary
bypass and extracorporeal membrane oxygenation.

Age, yrs

59.6  11.8

Female

21.2

21.5

0.93

Coronary artery disease*

86.4

87.2

0.75

Hypertension

56.6

57.4

0.83

average LOS in those who died was similar between

DM

21.6

21.1

0.86

the 2 groups (4.7 vs. 4.5 days; p ¼ 0.74). After pro-

1.8

1.0

0.35

pensity matching, there was no difference in the

Non–insulin-dependent
DM

19.8

20.1

0.94

average mortality-free LOS (12.3 vs. 10.4 days; p ¼ 0.06)

Congestive heart failure

33.6

33.5

0.98

or mortality-related LOS (4.7 vs. 4.2 days; p ¼ 0.39)

Pre-existing renal
dysfunction†

6.8

6.4

0.84

between those undergoing TH compared with those

Not on dialysis

5.8

5.4

0.82

On dialysis

1.0

1.0

0.99

DISCUSSION

0.53

Bare-metal stent

53.7

56.1

To the best of our knowledge, this is the largest study

Drug-eluting stent

46.3

43.9

1

63.0

61.3

ing TH. We performed a retrospective analysis on a

2

23.8

25.7

large in-patient population of CA patients admitted

3

10.5

10.0

across the country from 2006 to 2011. Major ﬁndings

2.7

3.0

2.8

3.7

0.53

Any bleeding
complications

15.6

15.4

0.95

Need for blood
transfusion‡

12.4

11.5

0.70

Abbreviations as in Table 1.

Comorbidities

Insulin-dependent DM

not undergoing TH.

PCI-related variables
Type of stent

Number of stents placed

$4
Vascular complications

to compare the incidence of stent thrombosis in pa0.93

of our study are as follows: 1) The incidence of stent
thrombosis after PCI in AMI patients presenting with
CA was 4.7%; and 2) TH did not increase the incidence
of stent thrombosis in CA patients with AMI undergoing PCI.

Shock/end-organ failure
Cardiogenic shock

tients with CA undergoing TH to those not undergo-

Clinical trial and registry data have demonstrated
48.7

51.8

0.42

stent thrombosis rates after PCI to be <1% (19). The

Noncardiogenic shock§

2.0

1.9

0.93

Hemodynamic support
use¶

33.6

36.6

0.41

Acute renal failure

29.7

29.5

0.96

The HORIZONS-AMI (Harmonizing Outcomes With

Not requiring dialysis

27.6

26.3

0.72

Revascularization and Stents in Acute Myocardial

Requiring dialysis or
hemoﬁltration

2.1

3.2

0.41

Infarction) trial reported an 0.8% incidence of acute

Acute liver failure

15.0

14.6

0.88

(within 24 h) deﬁnite or probable stent thrombosis

Acute respiratory failure

71.1

72.1

0.77

and 1.4% incidence of subacute (24 h to 30 days) stent

incidence of stent thrombosis may be higher in the
setting of acute coronary syndromes (ACS) (20–22).

Continued in the next column

thrombosis in patients undergoing primary PCI for
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T A B L E 4 Studies Showing Stent Thrombosis Incidence in CA Patients Undergoing PCI

Patient #

First Author
(Ref. #)

Year of
Country of No. of CA
No. of Stent
Stent Thrombosis
Publication
Origin
Patients Thrombosis Events
Incidence (%)

Comments

1

Knaﬂej et al. (24)

2007

Slovenia

72

1

1.4

32 patients underwent TH, 40 patients
had no TH. Stent thrombosis event
occurred in the TH group

2

Ibrahim et al. (11)

2011

Germany

57

4

7.0

27 patients underwent TH, 30 did not. All
stent thrombosis events occurred in
the TH group

3

Penela et al. (12)

2013

Spain

11

5

45.5

4

Joffre et al. (15)

2014

France

55

6

10.9

All patients underwent TH
All patients underwent TH

5

Rosillo et al. (14)

2014

Spain

77

2

2.6

All patients underwent TH

6

Gouffran et al. (25)

2015

France

101

11

10.9

All patients underwent TH

CA ¼ cardiac arrest; TH ¼ therapeutic hypothermia.

AMI (22,23). Other studies have demonstrated similar

collapse, rather than the use of hemodynamic sup-

ﬁndings in AMI patients not presenting as OHCA.

port, is responsible for the greater risk of stent

Penela et al. (12) reported an 0.7% rate of deﬁnite

thrombosis in this subgroup. In an unadjusted anal-

stent thrombosis after primary PCI, whereas Rosillo

ysis, we observed that the occurrence of bleeding or

et al. (14) reported a 1.2% incidence of acute stent

vascular complications and the need for blood trans-

thrombosis and a 1% incidence of subacute stent

fusions (due to bleeding or anemia) was associated

thrombosis in patients undergoing primary PCI for

with a higher incidence of stent thrombosis. The

STEMI. However, the incidence of stent thrombosis in

occurrence of anemia, bleeding, or vascular compli-

the setting of CA has been poorly studied.

cations often leads to interruption or discontinuation

There is a broad range of reported incidence of

of dual antiplatelet therapy after PCI, which in turn

stent thrombosis in CA patients in the literature,

pre-disposes to a higher risk of stent thrombosis (26).

ranging from 1.4% to 45.5% (Table 4) in various

In multivariate analysis, only the occurrence of

studies (11,12,14,15,24,25). Consistent with prior ob-

vascular complications (OR: 1.7; p ¼ 0.02) remained a

servations of a higher incidence of stent thrombosis

signiﬁcant predictor of stent thrombosis. Of note, we

in CA, we observed a 4.7% in-hospital stent throm-

also observed that stent thrombosis did not increase

bosis incidence in our population of CA patients.

in-hospital mortality in our patient population (24.8%

Because the NIS data pertain to a single hospitaliza-

with stent thrombosis vs. 26.4% without stent

tion, all stent thrombosis events in our study repre-

thrombosis; p ¼ 0.41). It is unclear why stent throm-

sent acute and subacute stent thrombosis only. The

bosis was not associated with an increased mortality

incidence of acute and subacute stent thrombosis in

risk; however, these ﬁndings are consistent with prior

our study (4.7%) was more than twice that reported in

observations of better than expected survival after

the HORIZONS-AMI trial (2.2%) (23), further afﬁrming

early stent thrombosis in the setting of CA (15,27).

a higher stent thrombosis risk in the CA population.

Several

mechanisms

have

been

proposed

to

Our study also identiﬁed several independent

explain the higher incidence of stent thrombosis in

predictors of acute and subacute stent thrombosis in

CA patients. The comatose state of patients after

the CA population. Advancing age (>80 years), pres-

resuscitation makes it difﬁcult to administer oral

ence of CHF or cardiogenic shock, and increasing

medications, which results in an inability to load

number of stent implantations resulted in a greater

these patients with dual antiplatelet therapy prior to

risk of stent thrombosis. It is reassuring that there

cardiac catheterization. Joffre et al. (15) in their pop-

was no association between the type of stent (bare

ulation of AMI patients undergoing PCI showed that

metal vs. drug eluting) and risk of stent thrombosis.

none of the patients who presented with CA received

Interestingly, we found a higher incidence of stent

dual antiplatelet therapy before PCI. Administration

thrombosis in patients receiving hemodynamic sup-

of antiplatelet agents via orogastric or nasogastric

port (OR: 1.3; p ¼ 0.04), in contrast with the con-

tubes after crushing the medications may result in

ventional belief that hemodynamic support has a

unreliable gastrointestinal absorption of these drugs.

protective effect on stent thrombosis. We propose

Additionally, shock and multiorgan failure after CA

that the need for hemodynamic support is actually a

can result in delayed absorption and metabolism of

marker of critical illness and circulatory collapse in

antiplatelet drugs (28), some of which are prodrugs

our patient population, and that the circulatory

(e.g., clopidogrel and prasugrel) and need to be
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metabolized by the liver to be converted to an active

adverse cardiovascular events, or recurrent infarction

metabolite. Additionally, the critical illness of the CA

between those who received TH and those who did not.

patients can result in a hypercoagulable and pro-

The mechanisms proposed to explain increased risk

thrombotic state (12,29). The residual effect of high

of stent thrombosis with TH include impaired meta-

doses of vasoconstrictor medications administered

bolism and bioavailability of antiplatelet drugs,

during cardiopulmonary resuscitation and a high

reduced or ineffective platelet inhibition in the

level of circulating catecholamines and inﬂammatory

presence of TH (34–36), TH-related enhanced throm-

cytokines in the immediate postresuscitation period

bogenicity, increased platelet activation, reduced

may also play an important role. Other proposed

adenosine diphosphate clearance, increased shedding

mechanisms to explain the greater risk of stent

of platelet microparticles, and TH-induced mast cell

thrombosis include no ﬂow followed by restoration of

degranulation (10,37–42). Indirect measures, such as

ﬂow associated with successful resuscitation, and

the platelet reactivity index (PRI), have been explored

associated myocardial microcirculatory and endo-

to evaluate the changes in platelet function associated

thelial dysfunction (30,31).

with TH (43). High PRI values are associated with a

The relationship between TH and stent thrombosis

higher incidence of arterial thromboembolic compli-

remains controversial, with a major limitation of

cations (44). In the ISAR SHOCK (Efﬁcacy Study of LV

inadequate power or sample size in the studies evalu-

Assist Device to Treat Patients With Cardiogenic

ating this association. The current literature and their

Shock) registry, Orban et al. (45) examined platelet

major ﬁndings on this topic are summarized below. In

reactivity and clinical outcomes (including stent

2011, Ibrahim (11) reported a 14.8% stent thrombosis

thrombosis) in patients with ACS complicated by

incidence in 27 CA patients undergoing TH and PCI,

cardiogenic shock undergoing PCI. Sixty-four patients

compared with no stent thrombosis events in 30 CA

who received TH were compared with 81 patients who

patients undergoing PCI but no TH. In 2013, Penela

did not receive TH. TH use was not associated with any

et al. (12) observed 5 stent thrombosis events in 11 CA

change in platelet reactivity, 30-day mortality, or re-

patients treated with mild TH, and concluded that the

infarction. Only 3 deﬁnite stent thrombosis events

risk of stent thrombosis is signiﬁcantly increased in

were identiﬁed, all in the TH group (5% vs. 0%;

patients undergoing TH. Kozinski et al. (13) showed no

p ¼ 0.09) (45). Ibrahim et al (35) examined PRI in pa-

stent thrombosis events in 37 OHCA patients with ACS

tients with ACS and CA, divided into those undergoing

undergoing TH and PCI. In 2014, Rosillo et al. (14)

TH (n ¼ 84) and those not undergoing TH (n ¼ 80).

reported a 2.7% incidence of stent thrombosis in 77

There was a signiﬁcantly higher PRI (and thereby less

patients undergoing TH and primary PCI, which was

platelet inhibition) in patients undergoing TH. The

not different from a 2.3% stent thrombosis incidence in

reduction in platelet inhibitory effect with TH was

1,414 patients undergoing primary PCI for STEMI dur-

seen with all 3 antiplatelet drugs (clopidogrel, prasu-

ing the same time period. Casella et al. (7) also showed

grel, and ticagrelor); however, it was most marked in

no stent thrombosis events in 45 CA patients under-

patients receiving clopidogrel (35).

going PCI and treatment with TH. Joffre et al. in 2014

It is evident that most studies looking at the rela-

(15) and Gouffran et al. in 2015 (25) observed a 10.9%

tionship between TH and stent thrombosis are small,

stent thrombosis incidence in their population of

single-center studies, with a limited number of pa-

respectively 55 and 101 patients undergoing TH after

tients in the TH group, ranging from 11 to 101 (Table 4).

primary PCI. In 2015, Erlinge et al. (32) in a combined

Owing to the small number of TH patients in these

analyses of 2 prospective randomized controlled

studies, there is a possibility that the higher incidence

trials (RAPID MI-ICE [Rapid Intravascular Cooling in

of stent thrombosis with TH may be due to chance (27).

Myocardial Infarction as Adjunctive to Percutaneous

Moreover, most studies on TH and stent thrombosis

Coronary Intervention] and CHILL-MI [Efﬁcacy of

either lack a control group or have non-CA AMI pa-

Endovascular Catheter Cooling Combined With Cold

tients as their control group. As discussed earlier, the

Saline for the Treatment of Acute Myocardial Infarc-

post-CA state itself can pre-dispose the patients to a

tion]) with a total of 140 patients (70 in each group),

higher risk of stent thrombosis. Therefore, in order to

reported only 1 patient in the TH group to have a

determine the true contribution of hypothermia to the

re-infarction; stent thrombosis was not mentioned

occurrence of stent thrombosis, it is important to

speciﬁcally (32). Finally, a recent meta-analysis by

compare the stent thrombosis rates in CA AMI patients

Villablanca et al. (33), including data from 6 random-

undergoing TH with those in CA AMI patients not un-

ized controlled trials (total 819 patients) to evaluate

dergoing TH. Our study is the largest reported study

the efﬁcacy and safety of TH in STEMI patients,

focusing on the relationship between TH and stent

showed no difference in all-cause mortality, major

thrombosis, including 1,193 TH patients from multiple
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hospitals across the United States, and using CA AMI

(4.7%). Using a large population-based retrospective

patients not undergoing TH as the comparison group.

analysis,

We observed that, although the incidence of acute and

not increase the risk of stent thrombosis in these

subacute stent thrombosis in CA AMI patients is high

patients.

we

show

that

the

use

of

TH

does

(4.7%), it is not higher in those undergoing TH (3.9%)
compared to those not undergoing TH (4.7%; p ¼ 0.16).
These ﬁndings persist after propensity matching to
account for baseline differences between the TH and
no TH groups.

FUTURE DIRECTIONS
The role of newer purinergic receptor G-protein
coupled 12 (P2Y 12) inhibitors (prasugrel and tica-

STUDY LIMITATIONS. Being an administrative data-

base relying on ICD-9 codes, the NIS is susceptible to
errors arising from coding inaccuracies. It is not
possible to track patients after being discharged from
the hospital. Therefore, all data are cross-sectional
and the event rates (including stent thrombosis) reported refer to index hospitalization only. Long-term
outcomes (e.g., long-term stent thrombosis rates)
cannot be assessed from this study. Of note, only
1,193 of 49,019 CA patients (2.4%) in our study population received TH. The reason behind this may be
the inability to precisely identify CA patients eligible

grelor) in the setting of CA is unclear and controversial, with some data showing improved platelet
inhibition (35), but more recent data showing surprisingly higher rates of stent thrombosis compared
with clopidogrel (25). The use of intravenous P2Y 12
inhibitors such as cangrelor can result in better
platelet inhibition, especially in the setting of CA;
however, it remains to be seen whether this translates
into a reduction in stent thrombosis events. Future
prospective studies and randomized controlled trials
are needed to explore the role of these medications in
AMI patients presenting with CA.

to receive TH due to the administrative nature of the
database. Hence, our denominator includes all CA

REPRINT REQUESTS AND CORRESPONDENCE: Dr.

patients, and not just the CA patients who would be

Neeraj Shah, Lehigh Valley Health Network, Department

eligible to receive hypothermia (e.g., those who

of Cardiology, 1250 South Cedar Crest Boulevard, Allen-

continue to remain unconscious after resuscitation).

town, Pennsylvania 18103. E-mail: neerajshah86@gmail.

Therefore, the TH rate in our study is clearly an un-

com.

derestimation; however, our study was not intended
at evaluating the TH rates. Stent thrombosis was

PERSPECTIVES

identiﬁed using ICD-9 diagnosis code 996.72; however, there is no information on whether the stent

WHAT IS KNOWN? Theoretically, alterations in platelet

thrombosis

or

reactivity and pharmacokinetics of antiplatelet agents with TH

possible stent thrombosis. There is no information

can pre-dispose resuscitated CA patients undergoing concomi-

about medication use in the NIS database; hence, it is

tant TH and PCI to a higher risk of acute and subacute stent

not possible to determine which patients received

thrombosis. However, the current literature contains only a

dual antiplatelet therapy before the PCI, and what

handful of small studies on this topic, which show an inconsistent

antithrombotic medications were administered dur-

relationship between TH and stent thrombosis.

events

were

deﬁnite,

probable,

ing or after the PCI (e.g., heparin, bivalirudin, glycoprotein IIb/IIIa inhibitors). There is no information in

WHAT IS NEW? Our large nationwide study including 49,109

the NIS database about angiographic features such as

patients with CA due to AMI admitted to hospitals across the

thrombus burden, stent size, TIMI (Thrombolysis In

United States from 2006 to 2011 showed that the overall

Myocardial Infarction) ﬂow post stent, any residual

incidence of stent thrombosis after PCI in these patients was

disease proximal or distal to the stent, stent edge

high (4.7%). However, the use of TH did not increase the

dissection, stent underexpansion or asymmetric

risk of stent thrombosis, indicating that TH can be safely

expansion, stent malapposition, or ﬁnal luminal

combined with primary PCI in AMI patients presenting as

diameter after stent placement, all of which have

cardiac arrest.

been shown to be predictors of stent thrombosis (19).
WHAT IS NEXT? The role of newer antiplatelet agents

CONCLUSIONS
There is a high incidence of stent thrombosis after

(prasugrel, ticagrelor, and cangrelor) to reduce the risk of acute
and subacute stent thrombosis in the setting of CA needs to be
explored.

primary PCI in AMI patients presenting with CA
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